Episode Summary
Executive Summary: Peter Attia examines obicetrapib, a next-generation CETP inhibitor, arguing it may finally succeed where prior drugs failed by powerfully lowering LDL/ApoB without off-target toxicity. He also highlights a pre-specified Broadway biomarker substudy suggesting attenuation of Alzheimer’s-linked plasma markers, especially in APOE4 carriers, while emphasizing the findings are promising but not proof of clinical benefit.
Main Topics: CETP biology and reverse cholesterol transport (Priority: 5/5): Explains how CETP transfers cholesterol esters from HDL to ApoB particles, reshaping HDL/LDL dynamics and affecting indirect reverse cholesterol transport. Why earlier CETP inhibitors failed (Priority: 5/5): Reviews torcetrapib, dalcetrapib, evacetrapib, and anacetrapib, emphasizing either off-target toxicity, insufficient ApoB/LDL lowering, or limited clinical outcome benefit. Obicetrapib’s lipid effects and clinical promise (Priority: 5/5): Describes phase 2/3 data showing substantial LDL, ApoB, and Lp(a) reductions, along with favorable metabolic signals and a plausible path to cardiovascular benefit. Lp(a) reduction and metabolic neutrality (Priority: 4/5): Highlights that obicetrapib lowered Lp(a) and may have neutral or beneficial effects on diabetes risk, which could improve its risk-benefit profile versus statins. APOE biology and Alzheimer’s disease risk (Priority: 5/5): Connects APOE4 to impaired lipid trafficking in the brain, increased oxidative/inflammatory stress, and earlier risk of cognitive decline. Broadway biomarker substudy in Alzheimer’s markers (Priority: 5/5): Summarizes the pre-specified biomarker analysis showing smaller rises in p-tau217 and other neurodegeneration markers, with the strongest signal in APOE4/4 participants. Need for prospective outcomes trials (Priority: 4/5): Argues that biomarker improvements are encouraging but require larger, longer trials with cognitive endpoints, imaging, and APOE-enriched cohorts to establish true prevention benefit.
Key Arguments: CETP inhibition is biologically coherent because it alters HDL-ApoB cholesterol exchange and can lower LDL/ApoB while raising HDL. Earlier CETP failures do not invalidate the class; they were often derailed by off-target toxicity or inadequate ApoB lowering rather than by CETP inhibition itself. Obicetrapib appears meaningfully different because it produces large LDL reductions on top of intensive background therapy. Lowering ApoB, not simply raising HDL, is likely what drives cardiovascular benefit. Obicetrapib also reduced Lp(a) by about one-third, which could add clinically meaningful benefit given Lp(a)’s causal risk role. The drug may be metabolically neutral or even favorable regarding diabetes risk, unlike statins’ small diabetes signal. APOE4 impairs brain lipid trafficking, so interventions that improve circulating functional HDL/APOA1 may plausibly help CNS lipid homeostasis. The most compelling Alzheimer’s signal is in APOE4/4 carriers, where obicetrapib was associated with a reduction in p-tau217 rather than continued rise. The Broadway findings are biomarker data, not proof of slowed dementia, so they should be viewed as hypothesis-generating. A dedicated prevention trial enriched for APOE4 carriers and including cognitive and imaging outcomes is warranted.
Data Points: HDL increase with obicetrapib: ~25% - Broadway biomarker substudy; expected CETP-class effect LDL-C reduction with obicetrapib: ~30% vs 3% increase in placebo - Broadway trial in patients on maximal lipid-lowering therapy ApoB reduction with obicetrapib: 16% vs 1.8% in placebo - Broadway trial Lp(a) reduction with obicetrapib: ~33% - Broadway trial; notable given Lp(a) is difficult to modify p-tau217 change overall: 5% increase placebo vs 2% increase obicetrapib - Broadway pre-specified Alzheimer’s biomarker substudy over 12 months p-tau217 in APOE carriers: 7%+ increase placebo vs 1.5% increase obicetrapib - Subgroup analysis in E3/E4 and E4/E4 participants p-tau217 in APOE carriers age >70: ~15% increase placebo vs 6% increase obicetrapib - Higher-risk subgroup in Broadway substudy p-tau217 in APOE4/4: 12.7% increase placebo vs ~8% decrease obicetrapib - Small but striking subgroup (n=29) with strongest signal NFL difference in APOE4/4: ~17% difference - Directional biomarker improvement in the APOE4/4 subgroup GFAP difference in APOE4/4: ~15% difference - Directional biomarker improvement in the APOE4/4 subgroup p-tau181 difference in APOE4/4: ~14% difference - Directional biomarker improvement in the APOE4/4 subgroup Aβ42/40 ratio difference in APOE4/4: ~8% difference - Directional biomarker improvement in the APOE4/4 subgroup p-tau to Aβ42/40 ratio difference in APOE4/4: ~23% difference - Most dramatic composite biomarker shift in the APOE4/4 subgroup Trial size for Broadway biomarker analysis: >1,500 participants - Median age 67, roughly two-thirds male, without dementia/cognitive impairment but with cardiovascular disease CETP inhibitor class history: 4 prior major programs discussed - Torcetrapib, dalcetrapib, evacetrapib, anacetrapib Obicetrapib phase 2 LDL reduction: ~50% additional LDL reduction - ROSE trial on top of high- or high-intensity statin therapy Obicetrapib phase 2 ApoB reduction: ~30% - ROSE trial Obicetrapib LDL reduction with ezetimibe: ~52% - OSHAN trial with 10 mg ezetimibe Obicetrapib LDL reduction in triple therapy: >60% - ROSE II trial with high-intensity statin + ezetimibe + obicetrapib Anacetrapib outcome benefit: ~9-10% reduction in coronary events; ~12% over extended follow-up - REVEAL trial, consistent with ApoB lowering Evacetrapib biomarker effect: HDL >100% increase; LDL ~30% fall; ApoB ~15% fall; Lp(a) ~20% decline - Biomarker trial, but clinical benefit not shown
Pivotal Quotes: "I haven't been as excited about any drug in the market or a drug that's about to enter the market as I am with respect to this drug." — Peter Attia: Expressing his overall enthusiasm for obicetrapib "The rise of HDL that matters, it's the fall of LDL or APOB that matters." — Peter Attia: Summarizing why earlier CETP inhibitors likely failed "This is a biomarker study. It's not a cognitive outcomes trial." — Peter Attia: Cautioning against overinterpreting the Alzheimer’s biomarker results
Implications: If confirmed in outcomes trials, obicetrapib could become a major LDL/ApoB-lowering therapy and a potential Alzheimer’s-prevention tool for APOE4 carriers. For now, the data justify larger, longer, genotype-enriched trials before routine use for brain protection.
About Peter Attia Drive
Expert insight on health, performance, longevity, critical thinking, and pursuing excellence. Dr. Peter Attia (Stanford/Hopkins/NIH-trained MD) talks with leaders in their fields.